Skip to Main Content

We set out to build a machine-learning classifier that predicts a clinically meaningful vaginal-microbiome state from a baseline metagenomic profile, using only public data. Because intervention-response labels proved unrecoverable from public deposits — probiotic/live-biotherapeutic response had zero read-joinable labels, and preterm-birth cohorts are dominated by V3–V4 16S that resolves L. iners from L. crispatus poorly — we selected the one abundant, per-sample, self-supervised target the data could support: next-day community-state-type (CST) transition. The cohort was PRJEB37731 (Danish daily shotgun metagenomics, 40 subjects, ~967 consecutive day-pairs), reached through a documented funnel of 90 public datasets → 30 mined publications → 4 candidate targets → 8 feasibility-vetted cohorts → 1. The classifier was engineered for rigor: 184 CLR-transformed species plus covariates, leave-one-subject-out cross-validation, honest baselines (prevalence, persistence, current-state), subject-clustered GEE for effect estimates, and a synthetic-data power analysis. The primary result was an honest negative — the full microbiome composition adds essentially nothing beyond the current-state label (transition AUROC 0.66, matched by a covariate baseline), and next-day onset of dysbiosis is unpredictable (AUROC 0.51–0.55; up to 5 days of memory does not help). We then tested the textbook claim that L. iners is a "gateway to dysbiosis." iners strongly predicts community movement (adjusted OR 5.87, 95% CI 3.15–10.94, p=2.5×10⁻⁸), but that movement is predominantly recovery toward L. crispatus (0.57) rather than descent to dysbiosis (0.24). L. iners marks mobility, not decline — a novel refinement of the field's model. Why it matters: BV recurs in >50% of women within 6–12 months, making treatment response fundamentally a prediction problem. This is a first-of-its-kind, fully leakage-safe attempt to predict near-term vaginal-microbiome dynamics from public data — it honestly maps what is and isn't predictable at current data scale, and delivers a reproducible pipeline ready for a future cohort with linked intervention outcomes.

Team

Placement

Participant

More from Built with Claude: Life Sciences

What I built. Lazarus is an agent that takes a dead research repository that is open, cited, and no longer runnable, and turns it back into a callable…

DoctorDean project preview

Diffuse midline glioma is a paediatric brainstem cancer that is almost uniformly fatal: about ninety percent of children die within two years, and the first…

Faith Ogundimu project preview

Hippocampus AI is the memory and reasoning engine for scientific discovery. Every experiment generates valuable knowledge, but that knowledge becomes…

Disruptors project preview

I used Claude to train a protein language model that can generate an extremophilic version of any enzyme, maintaining its function, while allowing it to…

Jaymin project preview

Many primates are sexually dichromatic — males and females are different colors. I wanted to know how that trait is built genetically, and how it evolved…

Tina Lasisi project preview

About Trialign is a patient-facing clinical trial matcher for oncology. A patient pastes a clinical note, uploads a record, or connects their EHR via SMART on…

Trialign project preview